UBS Group
MGX icon

UBS Group’s Metagenomi Therapeutics MGX Stock Holding History

UBS Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6K Sell
16,098
-9,001
-36% -$14K ﹤0.01% 7883
2025
Q4 		$40.7K Buy
25,099
+1,611
+7% +$3.49K ﹤0.01% 7331
2025
Q3 		$55.7K Sell
23,488
-95,433
-80% -$194K ﹤0.01% 7482
2025
Q2 		$176K Buy
118,921
+51,170
+76% +$80.1K ﹤0.01% 6807
2025
Q1 		$92.1K Buy
67,751
+28,701
+73% +$68.4K ﹤0.01% 7103
2024
Q4 		$141K Buy
39,050
+29,989
+331% +$72.4K ﹤0.01% 6668
2024
Q3 		$19.7K Buy
9,061
+6,903
+320% +$23.9K ﹤0.01% 7386
2024
Q2 		$8.8K Buy
2,158
+478
+28% +$3.28K ﹤0.01% 7778
2024
Q1 		$17.7K Buy
+1,680
New +$19.3K ﹤0.01% 6977

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group's MGX Position: Q1 2026 in Review

UBS Group reduced its Metagenomi Therapeutics (MGX) stake by 36% in Q1 2026, selling an estimated $14K and leaving 16,098 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7883.

UBS Group first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $176K in Q2 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • UBS Group held 16,098 shares of Metagenomi Therapeutics worth $21.6K as of Q1 2026.
  • UBS Group sold 9,001 Metagenomi Therapeutics shares in Q1 2026, an estimated $14K.
  • Metagenomi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7883 holding.
  • UBS Group first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's Metagenomi Therapeutics position peaked at $176K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.